Correlation of granulin expression in intracranial rneningiomas to clinical parameters
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Choong Hyun | - |
dc.contributor.author | Cheong, Jin Hwan | - |
dc.contributor.author | Kim, Jae Min | - |
dc.date.accessioned | 2022-12-20T17:58:19Z | - |
dc.date.available | 2022-12-20T17:58:19Z | - |
dc.date.created | 2022-08-27 | - |
dc.date.issued | 2010-05 | - |
dc.identifier.issn | 1792-0981 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/175038 | - |
dc.description.abstract | The granulins, a novel class of peptides from leukocytes, are growth factors that mediate cycle progression and the motility of epithelial and mesenchymal cells. They are also involved in tissue repair and tumorigenesis. We investigated granulin expression in intracranial meningiomas by reverse transcription-polymerase chain reaction and correlated its expression to clinical parameters. Seventy-nine patients who underwent tumor removal for intracranial meningiomas were included in this study. Granulin expression was analyzed in respect to clinical parameters including age, gender, tumor size and peritumoral brain edema (PTBE). Granulin was expressed in the tumors of 29 of 79 (36.7%) patients with intracranial meningiomas, and its presence or absence was correlated to tumor size and PTBE volume. However, granulin expression did not vary significantly according to patient age or gender. Our data provide improved understanding about the clinical implications of granulin expression in intracranial meningiomas. Additionally, our information suggests a potential role for granulin as a molecular target in the management of meningiomas. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.title | Correlation of granulin expression in intracranial rneningiomas to clinical parameters | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cheong, Jin Hwan | - |
dc.identifier.doi | 10.3892/etm_00000077 | - |
dc.identifier.scopusid | 2-s2.0-77956214439 | - |
dc.identifier.wosid | 000284799800015 | - |
dc.identifier.bibliographicCitation | EXPERIMENTAL AND THERAPEUTIC MEDICINE, v.1, no.3, pp.493 - 496 | - |
dc.relation.isPartOf | EXPERIMENTAL AND THERAPEUTIC MEDICINE | - |
dc.citation.title | EXPERIMENTAL AND THERAPEUTIC MEDICINE | - |
dc.citation.volume | 1 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 493 | - |
dc.citation.endPage | 496 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | EPITHELIN/GRANULIN PRECURSOR EXPRESSION | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | HUMAN MENINGIOMAS | - |
dc.subject.keywordPlus | PROGRANULIN | - |
dc.subject.keywordPlus | ACROGRANIN | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | SEQUENCE | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | CDNA | - |
dc.subject.keywordAuthor | granulin | - |
dc.subject.keywordAuthor | growth factor | - |
dc.subject.keywordAuthor | meningioma | - |
dc.subject.keywordAuthor | polymerase chain reaction | - |
dc.identifier.url | https://www.spandidos-publications.com/10.3892/etm_00000077 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.